{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T10:30:15Z","timestamp":1787913015276,"version":"build-2784847793"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T00:00:00Z","timestamp":1484870400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T00:00:00Z","timestamp":1484870400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["HORM CANC"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s12672-017-0284-7","type":"journal-article","created":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T14:58:54Z","timestamp":1484924334000},"page":"108-118","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Controlling Tumor Progression with Cyclophosphamide, Vincristine, and Dacarbazine Treatment Improves Survival in Patients with Metastatic and Unresectable Malignant Pheochromocytomas\/Paragangliomas"],"prefix":"10.1007","volume":"8","author":[{"given":"Shiko","family":"Asai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuyuki","family":"Katabami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Tsuiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhide","family":"Naruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,20]]},"reference":[{"key":"284_CR1","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1677\/ERC-07-0074","volume":"14","author":"A Chrisoulidou","year":"2007","unstructured":"Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB (2007) The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer 14:569\u2013585","journal-title":"Endocr Relat Cancer"},{"key":"284_CR2","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1677\/erc.1.00829","volume":"11","author":"G Eisenhofer","year":"2004","unstructured":"Eisenhofer G, Bornstein SR, Brouwers FM, Cheung NK, Dahia PL, de Krijger RR, Giordano TJ, Greene LA, Goldstein DS, Lehnert H, Manger WM, Maris JM, Neumann HP, Pacak K, Shulkin BL, Smith DI, Tischler AS, Young WF Jr (2004) Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer 11:423\u2013436","journal-title":"Endocr Relat Cancer"},{"key":"284_CR3","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/cen.12341","volume":"80","author":"LT van Hulsteijn","year":"2014","unstructured":"van Hulsteijn LT, Niemeijer ND, Dekkers OM, Corssmit EP (2014) (131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis. Clin Endocrinol 80:487\u2013501","journal-title":"Clin Endocrinol"},{"key":"284_CR4","doi-asserted-by":"publisher","first-page":"I18","DOI":"10.1161\/01.HYP.7.3_Pt_2.I18","volume":"7","author":"HR Keiser","year":"1985","unstructured":"Keiser HR, Goldstein DS, Wade JL, Douglas FL, Averbuch SD (1985) Treatment of malignant pheochromocytoma with combination chemotherapy. Hypertension 7:I18\u2013I24","journal-title":"Hypertension"},{"key":"284_CR5","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1055\/s-0031-1299707","volume":"44","author":"PF Plouin","year":"2012","unstructured":"Plouin PF, Fitzgerald P, Rich T, Ayala-Ramirez M, Perrier ND, Baudin E, Jimenez C (2012) Metastatic pheochromocytoma and paraganglioma: focus on therapeutics. Horm Metab Res 44:390\u2013399","journal-title":"Horm Metab Res"},{"key":"284_CR6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.7326\/0003-4819-109-4-267","volume":"109","author":"SD Averbuch","year":"1988","unstructured":"Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R, Keiser HR (1988) Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 109:267\u2013273","journal-title":"Ann Intern Med"},{"key":"284_CR7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/cen.12590","volume":"82","author":"T Deutschbein","year":"2015","unstructured":"Deutschbein T, Fassnacht M, Weismann D, Reincke M, Mann K, Petersenn S (2015) Treatment of malignant phaeochromocytoma with a combination of cyclophosphamide, vincristine and dacarbazine: own experience and overview of the contemporary literature. Clin Endocrinol 82:84\u201390","journal-title":"Clin Endocrinol"},{"key":"284_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12672-013-0133-2","volume":"4","author":"A Tanabe","year":"2013","unstructured":"Tanabe A, Naruse M, Nomura K, Tsuiki M, Tsumagari A, Ichihara A (2013) Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma. Horm Cancer 4:103\u2013110","journal-title":"Horm Cancer"},{"key":"284_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"284_CR10","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1002\/cncr.23812","volume":"113","author":"H Huang","year":"2008","unstructured":"Huang H, Abraham J, Hung E, Averbuch S, Merino M, Steinberg SM, Pacak K, Fojo T (2008) Treatment of malignant pheochromocytoma\/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer 113:2020\u20132028","journal-title":"Cancer"},{"key":"284_CR11","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/cen.12542","volume":"81","author":"ND Niemeijer","year":"2014","unstructured":"Niemeijer ND, Alblas G, van Hulsteijn LT, Dekkers OM, Corssmit EP (2014) Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. Clin Endocrinol 81:642\u2013651","journal-title":"Clin Endocrinol"},{"key":"284_CR12","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1002\/cncr.26577","volume":"118","author":"M Ayala-Ramirez","year":"2012","unstructured":"Ayala-Ramirez M, Feng L, Habra MA, Rich T, Dickson PV, Perrier N, Phan A, Waguespack S, Patel S, Jimenez C (2012) Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience. Cancer 118:2804\u20132812","journal-title":"Cancer"},{"key":"284_CR13","doi-asserted-by":"publisher","first-page":"R111","DOI":"10.1530\/EJE-14-0113","volume":"171","author":"E Baudin","year":"2014","unstructured":"Baudin E, Habra MA, Deschamps F, Cote G, Dumont F, Cabanillas M, Arfi-Roufe J, Berdelou A, Moon B, Al Ghuzlan A, Patel S, Leboulleux S, Jimenez C (2014) Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma. Eur J Endocrinol 171:R111\u2013R122","journal-title":"Eur J Endocrinol"},{"key":"284_CR14","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1097\/00000658-197405000-00029","volume":"179","author":"WH Remine","year":"1974","unstructured":"Remine WH, Chong GC, Van Heerden JA, Sheps SG, Harrison EG Jr (1974) Current management of pheochromocytoma. Ann Surg 179:740\u2013748","journal-title":"Ann Surg"},{"key":"284_CR15","first-page":"367","volume":"91","author":"JA van Heerden","year":"1982","unstructured":"van Heerden JA, Sheps SG, Hamberger B, Sheedy PF 2nd, Poston JG, ReMine WH (1982) Pheochromocytoma: current status and changing trends. Surgery 91:367\u2013373","journal-title":"Surgery"},{"key":"284_CR16","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1210\/jc.2013-1907","volume":"98","author":"S Hescot","year":"2013","unstructured":"Hescot S, Leboulleux S, Amar L, Vezzosi D, Borget I, Bournaud-Salinas C, de la Fouchardiere C, Lib\u00e9 R, Do Cao C, Niccoli P, Tabarin A, Raingeard I, Chougnet C, Giraud S, Gimenez-Roqueplo AP, Young J, Borson-Chazot F, Bertherat J, Wemeau JL, Bertagna X, Plouin PF, Schlumberger M, Baudin E (2013) One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 98:4006\u20134012","journal-title":"J Clin Endocrinol Metab"},{"key":"284_CR17","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/ncpendmet0396","volume":"3","author":"K Pacak","year":"2007","unstructured":"Pacak K, Eisenhofer G, Ahlman H, Bornstein SR, Gimenez-Roqueplo AP, Grossman AB, Kimura N, Mannelli M, McNicol AM, Tischler AS (2007) Pheochromocytoma: recommendations for clinical practice from the First International Symposium. Nat Clin Pract Endocrinol Metab 3:92\u2013102","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"284_CR18","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/jso.24063","volume":"112","author":"YM Choi","year":"2015","unstructured":"Choi YM, Sung TY, Kim WG, Lee JJ, Ryu JS, Kim TY, Kim WB, Hong SJ, Song DE, Shong YK (2015) Clinical course and prognostic factors in patients with malignant pheochromocytoma and paraganglioma: a single institution experience. J Surg Oncol 112:815\u2013821","journal-title":"J Surg Oncol"},{"key":"284_CR19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1182\/blood-2002-11-3343","volume":"102","author":"SM Smith","year":"2003","unstructured":"Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J, Vardiman JW, Rowley JD, Larson RA (2003) Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 102:43\u201352","journal-title":"Blood"},{"key":"284_CR20","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.1210\/jc.2007-0709","volume":"92","author":"L Amar","year":"2007","unstructured":"Amar L, Baudin E, Burnichon N, Peyrard S, Silvera S, Bertherat J, Bertagna X, Schlumberger M, Jeunemaitre X, Gimenez-Roqueplo AP, Plouin PF (2007) Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab 92:3822\u20133828","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Hormones and Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-017-0284-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12672-017-0284-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-017-0284-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T17:08:55Z","timestamp":1609261735000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12672-017-0284-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,20]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["284"],"URL":"https:\/\/doi.org\/10.1007\/s12672-017-0284-7","relation":{},"ISSN":["1868-8497","1868-8500"],"issn-type":[{"value":"1868-8497","type":"print"},{"value":"1868-8500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,20]]},"assertion":[{"value":"28 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research Involving Human Participants and\/or Animals"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}